Agios Pharmaceuticals, Inc. Earnings

Agios Pharmaceuticals, Inc.’s revenue jumped 43.69% since last year same period to $12.88Mn in the Q3 2025. On a quarterly growth basis, Agios Pharmaceuticals, Inc. has generated 3.41% jump in its revenue since last 3-months.

Agios Pharmaceuticals, Inc.’s net profit fell -110.91% since last year same period to $-103.43Mn in the Q3 2025. On a quarterly growth basis, Agios Pharmaceuticals, Inc. has generated 7.67% jump in its net profits since last 3-months.

Agios Pharmaceuticals, Inc.’s net profit margin fell -107.59% since last year same period to -803.05% in the Q3 2025. On a quarterly growth basis, Agios Pharmaceuticals, Inc. has generated 10.71% jump in its net profit margins since last 3-months.

Agios Pharmaceuticals, Inc.’s earning per share (EPS) estimates for the current quarter stand at -1.91 - a -9.14% fall from last quarter’s estimates.

Agios Pharmaceuticals, Inc.’s earning per share (EPS) estimates for the current year stand at -1.91.

Agios Pharmaceuticals, Inc.’s earning per share (EPS) jumped 100% since last year same period to 0 in the Q3 2025. This indicates that the Agios Pharmaceuticals, Inc. has generated 100% annual rate of jump in its earning per share (EPS) in the last 4 quarters.